Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2015; 7(11): 263-270
Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.263
Novel therapy for advanced gastric cancer
Yue Zhang, Shenhong Wu
Yue Zhang, Shenhong Wu, Division of Hematology and Oncology, Stony Brook University, Stony Brook, NY 11794-8151, United States
Author contributions: Zhang Y and Wu S contributed the same to this paper.
Conflict-of-interest statement: None to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yue Zhang, MD, MPH, Assistant Professor, Division of Hematology and Oncology, Stony Brook University, HSC 15-040, 101 Nicholls Rd, Stony Brook, NY 11794-8151, United States. yue.zhang@stonybrookmedicine.edu
Telephone: +1-631-6381000 Fax: +1-631-6380915
Received: June 18, 2015
Peer-review started: June 20, 2015
First decision: July 27, 2015
Revised: August 14, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: November 15, 2015
Core Tip

Core tip: Advanced gastric cancer (GC) has very poor outcome with chemotherapy remains the main treatment. There is an urgent unmet need to develop novel therapy for GC. Limited success is achieved for targeted therapy after trastuzumab for human epidermal growth factor receptor 2 positive disease. Ramucirumab was recently approved by Food and Drug Administration as a single agent or combined with paclitaxel in refractory advanced GC patients. Immune therapy and GC stem cell research are on the horizon.